Douglas J. Warner, MD
Douglas J. Warner, MD
Clinical Research Medical Director
Amgen Inc.
One Amgen Center Drive
Thousand Oaks,
CA
USA
91320
Papers:
4 - Seminal Abstract
A phase III, randomized, double-blind trialof weekly paclitaxel plus the angiopoientin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1
101 -Featured Poster
Evaluation of CA-125 response in the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer
138 - Scientific Plenary
Health-related quality-of-life analysis from the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer